Article

Activity Of Docetaxel, Carboplatin, And Doxorubicin In Patient-Derived Triple-Negative Breast Cancer Xenografts 

2020-08-12

Abstract excerpt

<h4>Background: </h4> Triple-negative breast cancer (TNBC) is highly responsive to neoadjuvant polychemotherapy regimens including anthracyclines, taxanes, and, more recently, carboplatin. However, there is inadequate information on the individual contribution of each of these agents to the global activity of the combinations, and the use of combinations of up to four of these drugs is associated with relevant tox...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 063eeb58-2b5d-56e7-bd61-f8cd2a03ba1e
DOI: 10.21203/rs.3.rs-57678/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Activity Of Docetaxel, Carboplatin, And Doxorubicin In Patient-Derived Triple-Negative Breast Cancer Xenografts DOI 10.21203/rs.3.rs-57678/v1Read

Patient-Derived Xenograft-Guided Prediction of Chemotherapy Response in Triple-Negative Breast CancerSemantic proximity Read

An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapySemantic proximity Read

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.Semantic proximity Read

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.Semantic proximity Read

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.Semantic proximity Read

Targeted Therapies for Triple-Negative Breast Cancer.Semantic proximity Read

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant stateSemantic proximity Read

Advances in the systemic treatment of triple-negative breast cancer.Semantic proximity Read

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trialSemantic proximity Read

Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell LinesSemantic proximity Read

Development of therapeutic approaches to 'triple negative' phenotype breast cancer.Semantic proximity Read

Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.Semantic proximity Read